Last $10.35 USD
Change Today +0.51 / 5.18%
Volume 1.0M
IMGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Key Developments

Ventana Medical Systems, Inc. Announces Collaboration to Develop Companion Diagnostics for ImmunoGen, Inc.'s Targeted Anticancer Agents

Ventana Medical Systems, Inc. announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancers (NSCLC). The goal of the collaboration is to leverage Ventana's expertise in companion diagnostic development, from prototyping through regulatory approval and commercialization, to identify specific patient populations for ImmunoGen's bio-target directed therapies. This pharma collaboration is one of dozens currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tools that help identify those individuals who are most likely to benefit from specific treatments. In addition to ImmunoGen, Ventana has announced collaborations with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more.

ImmunoGen, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014; Provides Earnings Guidance for the Fiscal Year 2015

ImmunoGen, Inc. reported unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company reported total revenues of $13,203,000 compared to $17,218,000 a year ago. Loss from operations was $21,910,000 compared to $11,337,000 a year ago. Net loss was $22,282,000 or $0.26 per basic and diluted share compared to $11,226,000 or $0.13 per basic and diluted share a year ago. Cash used in operations was $18.9 million compared with $23.6 million in the same period in last year. Capital expenditures were $1.7 million and $0.6 million for the first three months of fiscal year 2015 and fiscal year 2014, respectively. The company’s fiscal year 2015 financial guidance remains unchanged from that issued in August 2014. The company expects its revenues to be between $100 million and $105 million and net loss to be between $60 million and $65 million. Cash used in operations to be between $55 million and $60 million and its capital expenditures to be between $7 million and $9 million.

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. announced that Dr. James J. O'Leary, Vice President and Chief Medical Officer of the company of his intention to leave the company's employ in mid-October 2014 for personal reasons. His responsibilities will be assumed by Dr. Charles Q. Morris, Executive Vice President and Chief Development Officer, to whom Dr. O'Leary currently reports.

ImmunoGen, Inc. Hires Sandra E. Poole as Senior Vice President of Technical Operations

ImmunoGen, Inc. announced the appointment of Sandra E. Poole as Senior Vice President, Technical Operations. Ms. Poole brings to ImmunoGen more than 25 years of experience related to the development and manufacturing of innovative biopharmaceuticals, most recently as the senior vice president of biologics manufacturing at Genzyme. She reports to Daniel Junius, President and Chief Executive Officer of ImmunoGen.

ImmunoGen, Inc. to Report Q1, 2015 Results on Oct 24, 2014

ImmunoGen, Inc. announced that they will report Q1, 2015 results at 6:30 AM, US Eastern Standard Time on Oct 24, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $10.35 USD +0.51

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €8.95 EUR +0.039
BioInvent International AB kr2.88 SEK +0.04
Genmab A/S kr295.90 DKK +0.50
MorphoSys AG €79.42 EUR +1.54
Seattle Genetics Inc $36.79 USD +0.14
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.9x
Price/Book 15.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.